Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own38.03% Shs Outstand194.61M Perf Week40.78%
Market Cap150.82M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float120.59M Perf Month66.67%
Income- PEG- EPS next Q- Inst Own0.41% Short Float0.27% Perf Quarter31.38%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio2.17 Perf Half Y20.90%
Book/sh- P/B- EPS next Y- ROA- Short Interest0.32M Perf Year-25.48%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.41 - 1.27 Perf YTD38.39%
Dividend Est.- P/FCF- EPS past 5Y-12.98% ROI- 52W High-38.97% Beta0.57
Dividend TTM- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low89.02% ATR (14)0.09
Dividend Ex-Date- Current Ratio- EPS Y/Y TTM- Oper. Margin- RSI (14)78.44 Volatility29.15% 15.58%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price2.84
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q7.04% Payout- Rel Volume22.98 Prev Close0.75
Sales Surprise- EPS Surprise-2.57% Sales Q/Q- Earnings- Avg Volume148.59K Price0.77
SMA2057.82% SMA5055.85% SMA20028.00% Trades Volume2,513,051 Change2.84%
Date Action Analyst Rating Change Price Target Change
Dec-22-20Initiated B. Riley Securities Buy $8
Dec-17-18Initiated Laidlaw Buy
Apr-23-24 09:32AM
Apr-22-24 07:00AM
Apr-19-24 07:00AM
Apr-18-24 07:00AM
07:00AM Loading…
Apr-11-24 07:00AM
Mar-05-24 07:00AM
Jan-08-24 07:00AM
Jan-05-24 09:30AM
Dec-19-23 07:00AM
Dec-04-23 07:09AM
Nov-30-23 07:00AM
Nov-01-23 07:00AM
Oct-20-23 05:20AM
07:00AM Loading…
Oct-18-23 07:00AM
Oct-17-23 03:27AM
Oct-16-23 07:00AM
Oct-13-23 07:00AM
Oct-11-23 07:00AM
Sep-26-23 07:00AM
Sep-12-23 08:19AM
Sep-08-23 07:00AM
Sep-06-23 07:00AM
Aug-28-23 07:12AM
Aug-23-23 10:30AM
Aug-17-23 07:00AM
Aug-15-23 09:28AM
08:00AM Loading…
Aug-01-23 08:00AM
Jul-21-23 04:15PM
Jun-20-23 06:07AM
Jun-18-23 09:02AM
Jun-13-23 07:00AM
Jun-05-23 10:00AM
May-25-23 07:00AM
May-23-23 07:00AM
May-17-23 07:00AM
May-05-23 10:49AM
May-02-23 05:52AM
Apr-27-23 07:00AM
Apr-26-23 02:47PM
Apr-24-23 07:00AM
Apr-21-23 10:47AM
Apr-20-23 07:00AM
Apr-19-23 10:30AM
Apr-18-23 07:00AM
Apr-17-23 09:00AM
Apr-13-23 08:30AM
Apr-10-23 07:00AM
Apr-04-23 10:43AM
Mar-31-23 07:00AM
Mar-29-23 06:13AM
Mar-28-23 07:00AM
Mar-22-23 07:00AM
Mar-21-23 07:00AM
Mar-20-23 08:00AM
Mar-17-23 08:10AM
Mar-09-23 07:05AM
Mar-08-23 07:00AM
Feb-09-23 05:24AM
Jan-08-23 08:53AM
Jan-04-23 07:00AM
Jan-03-23 11:11AM
Dec-29-22 05:00PM
Dec-27-22 05:00PM
Dec-16-22 07:00AM
Dec-15-22 07:00AM
Dec-14-22 06:00AM
Dec-06-22 07:00AM
Dec-05-22 03:00AM
Nov-23-22 10:59AM
Nov-10-22 07:00AM
Nov-04-22 07:00AM
Nov-03-22 07:00AM
Nov-02-22 07:00AM
Oct-26-22 07:00AM
Oct-19-22 07:00AM
Oct-13-22 05:46AM
Oct-12-22 07:00AM
Sep-29-22 07:00AM
Sep-28-22 07:00AM
Sep-23-22 07:00AM
Sep-21-22 07:30AM
Sep-20-22 06:34AM
Sep-16-22 07:00AM
Sep-15-22 07:00AM
Sep-09-22 07:00AM
Aug-25-22 07:00AM
Aug-17-22 07:00AM
Aug-16-22 04:24PM
Aug-01-22 09:05AM
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.